Non-Cystic Fibrosis Bronchiectasis Treatment Market to Reach USD 3.5 Bn by 2035 at 5.8% CAGR, Driven by rising disease burden ...

One woman's journey from an unexpected diagnosis to learning how to manage a chronic, progressive lung disease.

Evercore 8th Annual Healthcare Conference December 2, 2025 11:15 AM ESTCompany ParticipantsSara Bonstein - Chief ...

The George Soros protege has generated legendary returns for decades, so it's hard not to take stock in where Druckenmiller ...

A study led by the Research Institute of the McGill University Health Center (The Institute) has identified a rare genetic ...

Mycosis fungoides is the most common subtype, making up the vast majority of CTCL cases. While early-stage disease has an estimated five-year survival rate of 88%, it remains a difficult-to-manage ...

Elexacaftor-tezacaftor-ivacaftor (ETI) may improve bronchial dilatations in adolescents with cystic fibrosis (CF).

Insmed Incorporated recently announced that the European Commission approved BRINSUPRI (brensocatib 25 mg tablets) for treating non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years and older ...

Respiratory medicine has witnessed substantial progress with the introduction of advanced lung function tests, particularly ...

A new study reveals that chulha smoke may be harming Indian women's lungs as severely as long-term cigarette smoking. Doctors ...

AN 86-year-old cyclist has taken on a unique challenge to scale the height of Olympus Mons. Whitehaven's Gerard McCarten ...